Abbott profit drops on lower drug sales

Abbott Laboratories' profit fell 2.6 percent as sales missed estimates, hurt by the rising dollar and growing generic competition to the anti-seizure medicine Depakote. The company's shares declined. Report

Suggested Articles

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.